Photo from Elisa Agostinetto/X
May 18, 2024, 04:13
Elisa Agostinetto: Is this a new predictive biomarker for PFS with camizestrant
Elisa Agostinetto, Clinical Research Fellow at Institute Jules Bordet, shared a post on X/Twitter:
”At ESMO Breast24 exploratory analysis of SERENA-2: compared to fulvestrant, camizestrant decreases ctDNA ESR1 mutations in ER+/HER2- mBC.
Is this a new predictive biomarker for PFS with camizestrant?”
Source: Elisa Agostinetto/X
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 19, 2025, 19:36
Apr 19, 2025, 19:17
Apr 19, 2025, 19:01
Apr 19, 2025, 18:42
Apr 19, 2025, 18:29
Apr 19, 2025, 17:53
Apr 19, 2025, 17:17